England's NICE To Focus On COVID-19 And Other Critical Therapies
Executive Summary
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
You may also be interested in...
HTA: Scotland Says Yes To Stelara For Ulcerative Colitis
The decision by the Scottish Medicines Consortium contrasts with recent draft guidance from England’s health technology assessment body, NICE, that recommended against the National Health Service using the Janssen product for ulcerative colitis.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.